Recent progress and treatment strategy of pectin polysaccharide based tissue engineering scaffolds in cancer therapy, wound healing and cartilage regeneration.

Natural polymers and its mixtures in the form of films, sponges and hydrogels are playing a major role in tissue engineering and regenerative medicine. Hydrogels have been extensively investigated as standalone materials for drug delivery purposes as they enable effective encapsulation and sustained release of drugs. Biopolymers are widely utilised in the fabrication of hydrogels due to their safety, biocompatibility, low toxicity, and regulated breakdown by human enzymes. Among all the biopolymers, polysaccharide-based polymer is well suited to overcome the limitations of traditional wound dressing materials. Pectin is a polysaccharide which can be extracted from different plant sources and is used in various pharmaceutical and biomedical applications including cartilage regeneration. Pectin itself cannot be employed as scaffolds for tissue engineering since it decomposes quickly. This article discusses recent research and developments on pectin polysaccharide, including its types, origins, applications, and potential demands for use in AI-mediated scaffolds. It also covers the materials-design process, strategy for implementation to material selection and fabrication methods for evaluation. Finally, we discuss unmet requirements and current obstacles in the development of optimal materials for wound healing and bone-tissue regeneration, as well as emerging strategies in the field.

Sunitinib loaded chitosan nanoparticles formulation and its evaluation.

The nano-polymeric pharmaceutical excipient such as chitosan nanoparticles (CS-NPs) were synthesized for formulating the anticancer drug Sunitinib (STB). The formulation was done through the simple ionic cross linking method. The prepared formulation was characterized by DLS, SEM, FT-IR and XRD. The DLS study reveals that the Sunitinib loaded chitosan nanoparticles (SNB-CS-NPs) were in the size range of < 200 nm. Encapsulation of Sunitinib and validation for the formulation was done using UV spectrophotometry. In vitro drug release and its cytotoxic studies were performed for STB-CS-NPs. This study implies the novel drug delivery system for Sunitinib for the effective sustained delivery.